These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 9663453

  • 1. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide.
    Wettergren A, Wøjdemann M, Holst JJ.
    Peptides; 1998; 19(5):877-82. PubMed ID: 9663453
    [Abstract] [Full Text] [Related]

  • 2. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs.
    Wøjdemann M, Wettergren A, Hartmann B, Holst JJ.
    Scand J Gastroenterol; 1998 Aug; 33(8):828-32. PubMed ID: 9754730
    [Abstract] [Full Text] [Related]

  • 3. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
    Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B.
    Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F, Fehmann HC, Göke R, Göke B.
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1.
    Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ.
    Scand J Gastroenterol; 2004 Apr; 39(4):353-8. PubMed ID: 15125467
    [Abstract] [Full Text] [Related]

  • 13. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man.
    Wettergren A, Maina P, Boesby S, Holst JJ.
    Scand J Gastroenterol; 1997 Jun; 32(6):552-5. PubMed ID: 9200286
    [Abstract] [Full Text] [Related]

  • 20. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
    Deacon CF, Plamboeck A, Møller S, Holst JJ.
    Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.